Alector, Inc. (ALEC) stock forecast & analysis
2.12
NasdaqGS · USD
Up: +0.13, +6.3%
1 analysis
- Open
- 2.08
- Previous close
- 1.99
- Day range
- 2.06 – 2.23
- 52-week range
- 1.09 – 3.40
- Volume (shares)
- 2.35M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 111.66M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 0.62
- Market cap
- 236.22M
Market Scanner’s AI analysis of Alector, Inc. (ALEC), updated October 2026: Alector's licensing deal with Genentech and Parkinson's program drove recent coverage, alongside mixed technical indicators and negative profitability.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Alector, Inc. (ALEC) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Alector's licensing deal with Genentech and Parkinson's program drove recent coverage, alongside mixed technical indicators and negative profitability.
Recent analyses for Alector (ALEC) covered a significant licensing agreement with Genentech for its AL050 program targeting neurodegenerative disorders, which resulted in a notable share price increase. The reports also examined the company's financial standing, noting strong short-term liquidity despite negative operating margins and declining revenue. Technical indicators presented a mixed picture, with short-term positive price changes contrasted by longer-term declines and price levels below key moving averages.
ALEC news & sentiment
News reports highlighted a significant positive development for Alector following a licensing agreement, which led to a notable increase in its share price. Social media discussions were not covered in the provided notes.
ALEC technical picture
Alector's stock exhibited mixed technical signals, with a positive short-term price change overshadowed by a significant 30-day decline. The price traded below key moving averages, while momentum indicators showed neutral readings alongside strong buying pressure and bearish MACD signals.
Fundamentals
Alector's recent financial reports showed declining year-over-year revenue and negative operating margins, alongside strong short-term liquidity. The company's valuation metrics, including forward P/E, were also noted as negative.
Factors discussed — upside
- Licensing agreement with Genentech valued at $1.27 billion.
- AL050 program targets Parkinson's disease and neurodegenerative disorders.
- Strong short-term liquidity with a Current Ratio of 5.26 and Quick Ratio of 5.05.
- High Money Flow Index (MFI) at 92.52 indicating strong buying pressure.
- Positive 7-day stock price change of +3.6%.
Factors discussed — risks
- Quarterly revenue growth year-over-year was -57.8%.
- Negative Operating Margin TTM of -912.4%.
- Negative Return on Equity TTM of -385.1%.
- Stock price trading below both the 50-day SMA and 200-day SMA.
- MACD below its signal line suggesting bearish momentum.
- Licensing agreements
- Neurodegenerative disorders
- Financial liquidity
- Technical indicators
Summary updated .
ALEC technical indicators
Common technical indicators for ALEC, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 2.03 | Price below |
| 10-day exponential moving average | 1.92 | Price above |
| Relative strength index (14-day) | 49.07 | Neutral |
| MACD line (12/26/9) | -0.0680 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 1.68 – 2.33 | Price inside the bands |
Analyses
Recent ALEC.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Alector, Inc.?
- The bull case for Alector centers on its significant licensing agreement with Genentech, valued at $1.27 billion, for its AL050 program targeting neurodegenerative disorders. This development, coupled with strong short-term liquidity and a high Money Flow Index indicating buying pressure, suggests potential upside.
- What are the risks for Alector, Inc.?
- Risks for Alector include a substantial year-over-year quarterly revenue decline of -57.8% and deeply negative operating and return on equity margins. The stock's technical picture also presents headwinds, with prices trading below key moving averages and bearish momentum indicated by the MACD.
- Is Alector, Inc. bullish or bearish?
- Recent AI analyses of Alector, Inc. examined factors on both sides. Discussed upside: The bull case for Alector centers on its significant licensing agreement with Genentech, valued at $1.27 billion, for its AL050 program targeting neurodegenerative disorders. This development, coupled with strong short-term liquidity and a high Money Flow Index indicating buying pressure, suggests potential upside. Discussed risks: Risks for Alector include a substantial year-over-year quarterly revenue decline of -57.8% and deeply negative operating and return on equity margins. The stock's technical picture also presents headwinds, with prices trading below key moving averages and bearish momentum indicated by the MACD. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Alector, Inc.?
- News reports highlighted a significant positive development for Alector following a licensing agreement, which led to a notable increase in its share price. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse Alector, Inc.?
- Every analysis of Alector, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh ALEC.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.